Forma Therapeutics agreed to help advance The Leukemia & Lymphoma Society (LLS) projects entering late preclinical development. The partnership will kick off with the selection of 10 small molecule candidates, discovered by LLS-funded academic researchers.


Forma will use its computational solvent mapping technology for structure-based drug design. The company will also leverage its computer modeling, screening, and medicinal chemistry competence to optimize and prioritize molecules that LLS and its partners may take to the clinic.








This site uses Akismet to reduce spam. Learn how your comment data is processed.